MAPT and Alzheimer disease: There are currently no FDA-approved drugs for the treatment of TBI, however, the shared pathology may indicate that AD treatments could be effective at treating the consequences of mTBI by reducing Aβ, tau hyperphosphorylation, and neuroinflammation.